Global Diabetic Nephropathy Market 2026-2035

Description

List of Tables

Diabetic Nephropathy Market Size, Share & Trends Analysis Report by Indication (Diabetes Type-1, and Diabetes Type-2), By Diagnosis (Urine Test, Imaging Test, Blood Test, Renal Function Test, and Renal Biopsy), and By Treatment (Medications, Kidney Dialysis, Kidney Transplant), Forecast Period (2026-2035)

Industry Overview

Diabetic nephropathy market was valued at $3,177.9 million in 2025 and is projected to reach $5,515.8 million by 2035, growing at a CAGR of 5.2% during the forecast period (2026-2035). The global diabetic nephropathy market is expanding steadily, driven by the rising prevalence of diabetes and the increasing incidence of kidney-related complications. Advancements in diagnostic methods have improved early detection and timely management of the disease. The growing availability of effective therapeutic options has enhanced patient outcomes and prolonged renal function. Healthcare systems are emphasizing preventive care and continuous monitoring to control disease progression. Increased investments in research are leading to the development of novel and targeted treatment approaches. These factors collectively contribute to the sustained growth of the diabetic nephropathy market globally.

Market Dynamics

Rising Adoption of Novel Therapeutic Classes

The diabetic nephropathy market is witnessing a growing shift toward advanced drug classes such as SGLT2 inhibitors and GLP-1 receptor agonists. These medications not only help regulate glucose levels but also provide renal protection and reduce cardiovascular risks. Their dual benefits have made them increasingly preferred among healthcare professionals. Continuous clinical trials are expanding their approved indications for kidney-related complications. Pharmaceutical companies are investing heavily in developing combination therapies to enhance treatment outcomes. This trend is redefining disease management and supporting long-term patient care.

Growing Emphasis on Early Diagnosis and Predictive Testing

There is an increasing focus on early detection of diabetic nephropathy through advanced diagnostic tools and biomarkers. Early screening enables timely therapeutic intervention, reducing the risk of kidney failure. The adoption of non-invasive and automated urine and blood analysis technologies is improving diagnostic precision. Healthcare systems are integrating digital platforms and AI-based models to identify high-risk patients more efficiently. These advancements are promoting preventive healthcare strategies in diabetes management. The shift toward predictive diagnostics is expected to improve patient outcomes and reduce treatment costs.

Market Segmentation

Based on the indication, the market is segmented into diabetes type-1, diabetes and type 2 diabetes.
Based on the diagnosis, the market is segmented into urine test, imaging test, blood test, renal function test, and renal biopsy.
Based on the treatment, the market is segmented into medications, kidney dialysis, and kidney transplants.

Diabetes Type-2 Segment to Lead the Market with the Largest Share

The increasing number of individuals affected by type 2 diabetes is a major contributor to the expansion of the diabetic nephropathy market. Rising cases linked to obesity, sedentary habits, and poor dietary patterns have intensified the disease burden globally. Type-2 diabetes often leads to long-term kidney complications, creating consistent demand for diagnostic and therapeutic interventions. Improved awareness and screening programs are enabling earlier identification of renal impairment among diabetic patients. Pharmaceutical advancements have also enhanced treatment options for this patient group. Consequently, the rising prevalence of Type-2 diabetes continues to drive the overall growth of the diabetic nephropathy market.

Urine Tests: A Key Segment in Market Growth

The market is expanding as urine tests remain a key diagnostic tool for identifying diabetic nephropathy in its early stages. This testing method is preferred for its non-invasive nature, cost efficiency, and ability to detect microalbuminuria, an early indicator of kidney damage. The growing focus on routine health monitoring among diabetic patients has further strengthened its use in clinical practice. Advancements in automated testing technologies have improved accuracy and reliability. Hospitals and diagnostic centers are increasingly incorporating these methods into regular screening programs. As a result, the widespread use of urine testing continues to play a central role in the growth of the diabetic nephropathy market.

Regional Outlook

The global diabetic nephropathy market is further divided by geography, including North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).

Rising Diabetic Population And Improving Healthcare Access in the Asia-Pacific

The Asia-Pacific region is witnessing rapid growth driven by the rising diabetic population and improving healthcare access. Urbanization, changing lifestyles, and dietary shifts have significantly increased the risk of kidney complications among diabetic patients. Governments and health agencies are promoting early screening initiatives to reduce the disease burden. Expanding pharmaceutical investments and the introduction of cost-effective diagnostic tools are supporting market development. Growing awareness about chronic kidney disease management is also enhancing treatment adoption. These combined factors are positioning the Asia-Pacific region as a key growth hub in the diabetic nephropathy market.

North America Region Dominates the Market with a Major Share

The North American market is expanding owing to the high incidence of diabetes and the strong presence of advanced healthcare infrastructure. Increased patient awareness and regular screening practices have led to earlier diagnosis and effective disease management. The region's access to innovative therapeutics and well-established reimbursement systems supports treatment adoption. Ongoing clinical research by leading pharmaceutical companies is further advancing therapy options. Lifestyle-related factors, including obesity and dietary habits, continue to elevate disease prevalence. Together, these elements contribute to the steady growth of the diabetic nephropathy market across North America.

Market Players Outlook

The major companies operating in the global diabetic nephropathy market include AstraZeneca PLC, Bayer AG, Novartis AG, Pfizer Inc., and Sanofi S.A., among others. Market players are leveraging partnerships, collaborations, mergers and acquisitions strategies for business expansion and innovative product development to maintain their market positioning.

Recent Developments

In November 2025, Bayer announced results from the pivotal Phase III FINE-ONE study, demonstrating that finerenone (Kerendia/ Firialta), in addition to standard of care, is superior to placebo in showing a statistically significant reduction in urine albumin-to-creatinine ratio (UACR) from baseline (ratio to baseline) over 6 months in adults with chronic kidney disease (CKD) associated with type 1 diabetes (T1D). Elevated UACR is associated with a higher risk of kidney disease progression and kidney failure and is a predictor of cardiovascular events.
In August 2024, Novartis announced that the US Food and Drug Administration (FDA) had granted accelerated approval for Fabhalta (iptacopan), a first-in-class complement inhibitor for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression. This is generally defined as a urine protein-to-creatinine ratio (UPCR) >=1.5 g/g1. Fabhalta specifically targets the alternative complement pathway of the immune system. When overly activated in the kidneys, the complement system is thought to contribute to the pathogenesis of IgAN1-4.

The Report Covers:

Market value data analysis of 2025 and forecast to 2035.
Annualized market revenues ($ million) for each market segment.
Country-wise analysis of major geographical regions.
Key companies operating in the global diabetic nephropathy market. Based on the availability of data, information related to new products and relevant news is also available in the report.
Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
Analysis of market-entry and market expansion strategies.
Competitive strategies by identifying 'who-stands-where' in the market.

Product Code: OMR2023732

1. Report Summary

Current Industry Analysis and Growth Potential Outlook
Global Diabetic Nephropathy Market Sales Analysis - Indication | Diagnosis | Treatment | ($ Million)
Diabetic Nephropathy Market Sales Performance of Top Countries
1.1. Research Methodology
Primary Research Approach
Secondary Research Approach
1.2. Market Snapshot

2. Market Overview and Insights

2.1. Scope of the Study
2.2. Analyst Insight & Current Market Trends
- 2.2.1. Key Diabetic Nephropathy Market Trends
- 2.2.2. Market Recommendations
2.3. Porter's Five Forces Analysis for the Diabetic Nephropathy Market
- 2.3.1. Competitive Rivalry
- 2.3.2. Threat of New Entrants
- 2.3.3. Bargaining Power of Suppliers
- 2.3.4. Bargaining Power of Buyers
- 2.3.5. Threat of Substitutes

3. Market Determinants

3.1. Market Drivers
- 3.1.1. Drivers For Global Diabetic Nephropathy Market: Impact Analysis
3.2. Market Pain Points and Challenges
- 3.2.1. Restraints For Global Diabetic Nephropathy Market: Impact Analysis
3.3. Market Opportunities

4. Competitive Landscape

4.1. Competitive Dashboard - Diabetic Nephropathy Market Revenue and Share by Manufacturers
Diabetic Nephropathy Product Comparison Analysis
Top Market Player Ranking Matrix
4.2. Key Company Analysis
- 4.2.1. AstraZeneca PLC
  - 4.2.1.1. Overview
  - 4.2.1.2. Product Portfolio
  - 4.2.1.3. Financial Analysis
  - 4.2.1.4. SWOT Analysis
  - 4.2.1.5. Business Strategy
- 4.2.2. Bayer AG
  - 4.2.2.1. Overview
  - 4.2.2.2. Product Portfolio
  - 4.2.2.3. Financial Analysis
  - 4.2.2.4. SWOT Analysis
  - 4.2.2.5. Business Strategy
- 4.2.3. Novartis AG
  - 4.2.3.1. Overview
  - 4.2.3.2. Product Portfolio
  - 4.2.3.3. Financial Analysis
  - 4.2.3.4. SWOT Analysis
  - 4.2.3.5. Business Strategy
- 4.2.4. Pfizer Inc.
  - 4.2.4.1. Overview
  - 4.2.4.2. Product Portfolio
  - 4.2.4.3. Financial Analysis
  - 4.2.4.4. SWOT Analysis
  - 4.2.4.5. Business Strategy
- 4.2.5. Sanofi S.A
  - 4.2.5.1. Overview
  - 4.2.5.2. Product Portfolio
  - 4.2.5.3. Financial Analysis
  - 4.2.5.4. SWOT Analysis
  - 4.2.5.5. Business Strategy
4.3. Top Winning Strategies by Market Players
- 4.3.1. Merger and Acquisition
- 4.3.2. Product Launch
- 4.3.3. Partnership And Collaboration

5. Global Diabetic Nephropathy Market Sales Analysis by Indication ($ Million)

5.1. Diabetes Type-1
5.2. Diabetes Type-2

6. Global Diabetic Nephropathy Market Sales Analysis by Diagnosis ($ Million)

6.1. Urine Test
6.2. Imaging Test
6.3. Blood Test
6.4. Renal Function Test
6.5. Renal Biopsy

7. Global Diabetic Nephropathy Market Sales Analysis by Treatment ($ Million)

7.1. Medications
7.2. Kidney Dialysis
7.3. Kidney Transplant

8. Regional Analysis

8.1. North American Diabetic Nephropathy Market Sales Analysis - Indication | Diagnosis | Treatment | Country ($ Million)
Macroeconomic Factors for North America
- 8.1.1. United States
- 8.1.2. Canada
8.2. European Diabetic Nephropathy Market Sales Analysis - Indication | Diagnosis | Treatment | Country ($ Million)
Macroeconomic Factors for Europe
- 8.2.1. UK
- 8.2.2. Germany
- 8.2.3. Italy
- 8.2.4. Spain
- 8.2.5. France
- 8.2.6. Russia
- 8.2.7. Rest of Europe
8.3. Asia-Pacific Diabetic Nephropathy Market Sales Analysis - Indication | Diagnosis | Treatment | Country ($ Million)
Macroeconomic Factors for Asia-Pacific
- 8.3.1. China
- 8.3.2. Japan
- 8.3.3. South Korea
- 8.3.4. India
- 8.3.5. Australia & New Zealand
- 8.3.6. ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And Other)
- 8.3.7. Rest of Asia-Pacific
8.4. Rest of the World Diabetic Nephropathy Market Sales Analysis - Indication | Diagnosis | Treatment | Country ($ Million)
Macroeconomic Factors for Rest of the World
- 8.4.1. Latin America
- 8.4.2. Middle East and Africa

9. Company Profiles

9.1. Abbott Laboratories
- 9.1.1. Quick Facts
- 9.1.2. Company Overview
- 9.1.3. Product Portfolio
- 9.1.4. Business Strategies
9.2. AstraZeneca PLC
- 9.2.1. Quick Facts
- 9.2.2. Company Overview
- 9.2.3. Product Portfolio
- 9.2.4. Business Strategies
9.3. Aurobindo Pharma Ltd.
- 9.3.1. Quick Facts
- 9.3.2. Company Overview
- 9.3.3. Product Portfolio
- 9.3.4. Business Strategies
9.4. Bayer AG
- 9.4.1. Quick Facts
- 9.4.2. Company Overview
- 9.4.3. Product Portfolio
- 9.4.4. Business Strategies
9.5. Boehringer Ingelheim International GmbH
- 9.5.1. Quick Facts
- 9.5.2. Company Overview
- 9.5.3. Product Portfolio
- 9.5.4. Business Strategies
9.6. Bristol-Myers Squibb Company
- 9.6.1. Quick Facts
- 9.6.2. Company Overview
- 9.6.3. Product Portfolio
- 9.6.4. Business Strategies
9.7. Cipla Inc.
- 9.7.1. Quick Facts
- 9.7.2. Company Overview
- 9.7.3. Product Portfolio
- 9.7.4. Business Strategies
9.8. Dr. Reddy's Laboratories Ltd.
- 9.8.1. Quick Facts
- 9.8.2. Company Overview
- 9.8.3. Product Portfolio
- 9.8.4. Business Strategies
9.9. Eli Lilly and Co.
- 9.9.1. Quick Facts
- 9.9.2. Company Overview
- 9.9.3. Product Portfolio
- 9.9.4. Business Strategies
9.10. Endo International plc
- 9.10.1. Quick Facts
- 9.10.2. Company Overview
- 9.10.3. Product Portfolio
- 9.10.4. Business Strategies
9.11. F. Hoffmann-La Roche Ltd.
- 9.11.1. Quick Facts
- 9.11.2. Company Overview
- 9.11.3. Product Portfolio
- 9.11.4. Business Strategies
9.12. Johnson & Johnson
- 9.12.1. Quick Facts
- 9.12.2. Company Overview
- 9.12.3. Product Portfolio
- 9.12.4. Business Strategies
9.13. Lupin Ltd.
- 9.13.1. Quick Facts
- 9.13.2. Company Overview
- 9.13.3. Product Portfolio
- 9.13.4. Business Strategies
9.14. Merck & Co., Inc.
- 9.14.1. Quick Facts
- 9.14.2. Company Overview
- 9.14.3. Product Portfolio
- 9.14.4. Business Strategies
9.15. Novartis AG
- 9.15.1. Quick Facts
- 9.15.2. Company Overview
- 9.15.3. Product Portfolio
- 9.15.4. Business Strategies
9.16. Pfizer Inc.
- 9.16.1. Quick Facts
- 9.16.2. Company Overview
- 9.16.3. Product Portfolio
- 9.16.4. Business Strategies
9.17. Sanofi S.A.
- 9.17.1. Quick Facts
- 9.17.2. Company Overview
- 9.17.3. Product Portfolio
- 9.17.4. Business Strategies
9.18. Sun Pharmaceutical Industries Ltd.
- 9.18.1. Quick Facts
- 9.18.2. Company Overview
- 9.18.3. Product Portfolio
- 9.18.4. Business Strategies
9.19. Takeda Pharmaceutical Co., Ltd.
- 9.19.1. Quick Facts
- 9.19.2. Company Overview
- 9.19.3. Product Portfolio
- 9.19.4. Business Strategies
9.20. Teva Pharmaceutical Industries Ltd.
- 9.20.1. Quick Facts
- 9.20.2. Company Overview
- 9.20.3. Product Portfolio
- 9.20.4. Business Strategies